






Amyloidosis Therapy Order Form Amvuttra (vutrisiran), Onpattro (patisiran)

Patient Name:						
Address:		City:			State:	Zip:
. For new patient	s, please submit with forr	m·				
	•					
□ Patient der						
☐ History & p						
, ,	bs and test results					
. Patient Informa						
□Male □Fe	male Height:i	n/cm Weight:	lbs/kg	□NKDA	Allergies:	
	: dose? □Yes □No, date o					
	oplicable): □PIV □PICC			_		
	linical Information					
_	ppathic heredofamilial am	vloidosis (polyneuropa	athy of here	editary tran	sthvretin-media	ted amyloidosis)
	0 code: Desc		-	-		, , , , , , , , , , , , , , , , , , , ,
					-	
l. Prescription Info	ormation					
Medication	□ Amvuttra (vutrisiran): 2	25 mg (0.5 ml.) subcut:	aneously or	nce every 3	months	
	□ Onpattro (patisiran): 0.	= '	-	-		on once every 3 weeks
	□Other:	5 1116/116 up to 111ux or	30 1116 (1116		18 / 17 111 4310	monde every 5 weeks
	☐ Amvuttra : Administer	subcutaneously as dire	ected ner n	nanufacture	er guidelines	
Directions	☐ Onpattro : Filter and th					pag containing NS for a
	total volume of 200 m					
	approximately 80 minu	-			-	
	☐ Other:					
Quantity /	☐ Dispense 1 dose / Refil	I x 12 months □Othe	r:			
Refills	Dispense all medical supp	olies necessary for IV in	nfusion or S	SUBQ inject	on	
6. Additional Orde	rs					
 Amvuttra Pr 	e-medications: <i>No</i> pre-me	edications unless orde	red:			
	e-medications: Give the fo					
	ethylprednisolone 80mg (OR mg) slow IV	push (or ar	n equivalen	t corticosteroid,	substitution if needed by
·	nacy)					
	phenhydramine 50 mg (O					
	motidine 20 mg (OR	mg) slow IV push	(or an equi	valent H2 b	locker, substitut	ion if needed by
	nacy)	· (OD				
_	cetaminophen 500-650mg		louth			
□ 0t	her:					
☑ RN to start	peripheral IV or use existi	ng CVC for Onpattro ir	nfusions. Ri	N to admini	ster catheter flu	shing per PromptCare
Policy and F		6				. 01
☑ RN to instru	uct patient to hydrate pre,	/post infusion and edu	icate on tak	king OTC dip	henhydramine	and/or acetaminophen
	cturer dosing recommend					·
	tor patient for minimum or possible side effects, aller					ng Amvuttra injection, ar

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.



newreferral@promptcare.com



Epinephrine IM/SQ (1 mg/mL v	phylaxis kit to be dispensed and dosed per p vial), diphenhydramine IV/IM (50 mg/mL vial 				
Prescriber Information					
Prescriber Name:	Office Cor	Office Contact:			
Address:		State:			
Phone:					
License No.:	DEA NO.:	NPI:			
Physician Signature		Physician Signature (Dispense as Written)			

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.